Archana Sidagouda Patil

Archana Sidagouda Patil


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2024 in Future Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
PPPradnya G. Patted
Pradnya G. Patted
RMRajashree S. Masareddy
Rajashree S. Masareddy
APArchana Sidagouda Patil
Archana Sidagouda Patil
RKRavikiran R. Kanabargi
Ravikiran R. Kanabargi
CBChetan T. Bhat
Chetan T. Bhat
Background: In recent years, public awareness of healthy diets has significantly increased, leading to a rise in the consumption of nutritional supplements. Among these, omega-3 fatty acids have become particularly popular. n − 3 polyunsaturated fatty acids (PUFAs) are widely distributed in marine and terrestrial environments. The primary sources of marine n − 3 fatty acid supplements are oily fish, such as anchovies, sardines and mackerel. Recently, they have drawn considerable attention for their potential therapeutic benefits in treating a range of illnesses, including cancer, neurological disorders, cardiovascular diseases, immunological and reproductive diseases, respectively. Main text: This study explores the many activities of n − 3 PUFAs, highlighting their importance in cellular processes that include signaling pathways, cell membrane integrity and structural maintenance. These fatty acids significantly regulate important physiological functions including the neurological system, blood pressure control, hematopoiesis, glucose metabolism and inflammatory responses. The latter highlights the wide therapeutic range of n − 3 PUFAs is especially notable considering the implications for controlling inflammatory disorders. Furthermore, the chemistry and dietary sources of omega-3 fatty acids are clarified in this review, which also sheds light on the complex molecular pathways that support the therapeutic efficacy of these fats and their bioavailability. The most recent information on the FDA's approval of omega-3 oils for use in formulation development highlights the compounds' adaptability and potential influence on the development of novel medications. Conclusion: A thorough analysis of omega-3 polyunsaturated fatty acids reveals both their remarkable therapeutic potential against a variety of diseases and their essential place in a normal diet. This study adds to the increasing amount of data that supports the use of n − 3 PUFAs in preventative and therapeutic approaches that are meant to improve human health and well-being by clarifying their mechanisms of action and emphasizing their applicability in formulation and development.

18 July 2023 in Therapeutic Delivery
Verified
Journal Article
Closed access
RPRachana D Pockle
Rachana D Pockle
RMRajashree S Masareddy
Rajashree S Masareddy
APArchana Sidagouda Patil
Archana Sidagouda Patil
PPPragati D Patil
Pragati D Patil
The effectiveness of pharmaceutical drugs depends not only on their active components and manufacturing processes, but also on the role played by pharmaceutical excipients. The traditional definiti... Plain language summary Excipients are matter we add to medicine when we make it. They give the medicine different qualities, like making it easier to dissolve, stick together, or slide smoothly. Bu...

28 October 2021 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
APArchana Sidagouda Patil
Archana Sidagouda Patil
RHRiya Hegde
Riya Hegde
AGAnand P. Gadad
Anand P. Gadad
PDPanchaxari M. Dandagi
Panchaxari M. Dandagi
RMRajashree Masareddy
Rajashree Masareddy
UBUday Bolmal
Uday Bolmal
Lovastatin is an antilipidemic drug that belongs to the class of statins that has poor oral bioavailability due to its low solubility and variable dissolution rate. The main aim of this study was to enhance the solubility and dissolution rate of the drug and understand its oral bioavailability. Lovastatin nanosuspension was formulated using a solventanti-solvent method using a probe sonication technique. A nanosuspension was prepared, using hydroxypropyl methylcellulose (HPMC) K15M and pluronic F68 as stabilizers. The formulated nanosuspensions were characterized for particle size, polydispersity index (PDI) zeta potential, surface morphology, and in vitro release rate. Further, an in vivo bioavailability study and stability studies were also performed. Optimized formulation showed a particle size of 127±0.01 nm, a PDI of 0.492±0.001, and a zeta potential of -37.9 mV, which indicates good stability. Morphological study showed that the particles were in the nano range. The drug content was found to be in the range of 73-87%. In vitro release revealed much faster release of the drug in one hour compared to the pure drug and its marketed formulation. In vivo bioavailability study was carried out in Wistar rats, which showed improvement in bioavailability by approximately 2.5 folds compared with the marketed formulation. Stability studies indicated that the optimized formulation F2 was more stable at 4°C±2°C. The prepared lovastatin nanosuspension showed improvement in solubility, dissolution rate, and oral bioavailability compared to the pure drug and its marketed formulation. Hence, lovastatin nanosuspension may be a potentially valuable tool for improving the oral bioavailability of lovastatin.

8 January 2021
Verified
Book Chapter
Closed access
PDF file
APArchana Sidagouda Patil
Archana Sidagouda Patil
AGAnand Panchakshari Gadad
Anand Panchakshari Gadad
PDPanchaxari Mallappa Dandagi
Panchaxari Mallappa Dandagi

27 January 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
ARAbhishek A. Revankar
Abhishek A. Revankar
APArchana Sidagouda Patil
Archana Sidagouda Patil
RKReshma Karishetti
Reshma Karishetti
KCKrutuja R. Chougule
Krutuja R. Chougule
PPPriyanka Patil
Priyanka Patil
ASAbhijit Salokhe
Abhijit Salokhe
Background: Parkinson’s disease (PD) is the second most prevalent neurological disorder, characterized by motor symptoms such as tremor and rigidity due to the degeneration of dopaminergic neurons in the substantia nigra. This study investigates the formulation of quercetin, a natural bioflavonoid with potent antioxidant and anti-inflammatory properties, as niosomes for intranasal delivery to enhance its bioavailability and therapeutic potential for PD.Methods: The niosomal formulation was optimized for critical parameters including particle size, entrapment efficiency, and zeta potential. Male Wistar rats were utilized to assess the effects of quercetin-loaded niosomes on motor function, dopaminergic neuron protection, and oxidative stress alleviation.Results: The optimized niosomal formulation exhibited a particle size of 195 nm, a polydispersity index (PDI) of 0.29, a zeta potential (ZP) of −30.63 mV, and an entrapment efficiency (EE) of 82.77%. In vivo evaluations conducted using the haloperidol-induced PD model revealed significant enhancements in behavioural, biochemical, and histopathological outcomes when compared to both disease controls and the standard treatment group. Additionally, short-term stability tests confirmed the robustness of the formulation.Conclusion: The findings suggest that the quercetin-loaded niosomal formulation offers improved drug delivery and efficacy, indicating its potential as a superior treatment option for PD compared to conventional dosage forms. This approach may pave the way for enhanced therapeutic strategies targeting the neurodegenerative processes underlying Parkinson’s disease.

2 June 2023 in Topics in Catalysis
Verified
Journal Article
Closed access
PDF file
PSPriya Shetti
Priya Shetti
SJSunil S. Jalalpure
Sunil S. Jalalpure
APArchana Sidagouda Patil
Archana Sidagouda Patil
KKKirtanjot Kaur
Kirtanjot Kaur